Form 4: Director Awarded Stock Options at Pasithea Therapeutics

Pasithea Therapeutics Corp. director Alfred J. Novak was granted stock options exercisable at $0.84 per share, vesting in one year or upon a change in control.

Summary

• Alfred J. Novak, a Director at Pasithea Therapeutics Corp. (KTTA), was granted stock options on May 1, 2026.
• The options have an exercise price of $0.84 per share.
• A total of 152,783 stock options were granted.
• These options are set to fully vest on the one-year anniversary of the grant date, provided Novak remains a director.
• Vesting will also occur immediately upon a 'Change in Control' as defined by the Issuer's 2023 Stock Incentive Plan.
• The underlying securities are 152,783 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director stock option grant without immediate financial impact or significant strategic revelations.

Positives

• Director compensation through stock options aligns the interests of management with shareholders.
• The grant of options suggests confidence in the company's future performance, potentially leading to share price appreciation.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• The exercise price of $0.84 indicates that the options will only be profitable if the stock price rises above this level.
• The filing does not provide details on the total compensation package or the rationale behind this specific grant amount.

Risks

• The value of the stock options is directly tied to the future performance of Pasithea Therapeutics Corp.'s stock price.
• If the stock price does not exceed the exercise price of $0.84, the options may expire worthless.
• The 'Change in Control' clause could lead to accelerated vesting, potentially benefiting the director in a scenario that may not be ideal for all shareholders.

Future Outlook

The stock options are exercisable at $0.84 and will vest in full on the one-year anniversary of the grant date or upon a change in control, indicating a forward-looking incentive tied to continued directorship and potential company events.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term value creation and align executive interests with shareholder returns, especially for companies like Pasithea Therapeutics Corp. that may be in development or growth phases.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment if stock price rises, but also potential for dilution if options are exercised and stock price does not significantly increase.
• Director (Alfred J. Novak): Receives an incentive tied to company performance and continued service.
• Employees: May view this as a positive sign of management commitment, but no direct impact on their compensation is indicated.

Next Steps

• Alfred J. Novak will continue to serve as a Director.
• The stock options will vest on May 1, 2027, or upon a Change in Control.
• The company may experience increased shareholder alignment if the stock price appreciates above $0.84.

Key Dates

Keywords

stock options, director compensation, Pasithea Therapeutics, KTTA, Form 4, SEC filing, beneficial ownership, equity award, vesting schedule, change in control